Drug Profile
ANGX 1039
Alternative Names: ANGX-1039Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Angiogenix Inc
- Class Vasodilators
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Intermittent claudication
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Intermittent-claudication in USA
- 02 Mar 2006 This compound is still in active development for Intermittent claudication
- 01 Jul 2004 Phase-I clinical trials in Intermittent claudication in the USA (unspecified route)